期刊文献+

败血症患者血栓调节蛋白及血小板参数的变化规律 被引量:2

The variation of platelet and thrombomodulin in patients with sepsis
下载PDF
导出
摘要 目的观察败血症患者血栓调节蛋白、血小板、平均血小板容积、血小板容积分布宽度及大血小板比率的变化规律。方法对2006年8月至2007年6月血培养阳性者进行血栓调节蛋白、血小板及其参数的测定,并与健康体检者进行比较。结果败血症患者血栓调节蛋白、血小板及其参数与健康体检者的结果有显著性差异:TM分别为79.93±29.17μg/L和20.40±7.72μg/L,MPV分别为12.11±1.43 fl和10.98±1.01,PLT分别为172±84×109/L和212±65×109/L,P-LCR分别为41.14±11.63%和30.95±8.88%,PDW分别为15.41±3.88 fl和13.74±2.51 fl,P均<0.01。结论败血症患者血小板及血栓调节蛋白会发生质和量的变化,表示病原体感染可影响机体凝血系统的功能并损害血管内皮细胞。 Objective Study the variation of the parameters of platelets and thrombomodulin(TM) in patients with sepsis.Methods Platelets(PLT),mean platelet volume(MPV),platelet distribution width(PDW)and platelet-large cell ratio(P-LCR) and TM were measured of 98 patients during episodes of culture-proven sepsis,at the same time,100 health peoples served as controls.Resuits In patients with sepsis, the parameters of platelet changed significantly. The platelet count was 172±84×10^9/L in patients with sepsis and 212±65 × 10^9/L in controls, MPV wasl2.11±1.43 fl vs10.98 ±1.01fl, P-LCR was41.14±11.63 % vs 30.95±8. 88 %, PDW wasl5.41±3.88fl vs13.74 ±2.51 fl, TM were 79.93± 29.17 μg/L vs 20.40±7.72 μg/L. All P 〈 0.01. Conclusion The platelets' parameters and TM in patients with sepsis changed significantly, it means microorganism infection can damage the endothelial cell and play an important role in the production and consumption of the platelet in patients with sepsis.
作者 王顺 陈丽波
出处 《中国实验诊断学》 2008年第10期1295-1296,共2页 Chinese Journal of Laboratory Diagnosis
关键词 血栓调节蛋白 败血症 血小板 平均血小板容积 sepsis thrombomodulin platelet mean platelet volume
  • 相关文献

参考文献6

  • 1Iqbal O, Messmore H, Fareed J, etal, Antithrombotic agents in the treatment of severe sepsis[J] .Expert Opin Emerg Drugs,2002,7(1) :111.
  • 2Levi M. Platelets in sepsis[ J]. Hematology,2005, (10) 1 : 129.
  • 3Lin SM, Wang YM, Lin HC, etal. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis[J ]. Crit Care Med,2008,36(3) :683.
  • 4Borgel D, Bomstain C, Reitsma PH, etal. A comparative study of the protein C pathway in septic and nonseptic patients with organ failure[J] .Am J Respir Crit Care Med,2007,176(9) :878.
  • 5艾宇航,张丽娜,龚华,徐道妙,赵双平,陈江辉.低分子肝素治疗脓毒症的前瞻性临床研究[J].中国危重病急救医学,2005,17(12):736-739. 被引量:43
  • 6Gullo A, Iscra F, Di Capua G, et al. Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock[ J]. Minerva Anestesiol, 2005,71 (12): 785.

二级参考文献13

  • 1焦华波,乔治,谭向龙,杜俊东,费阳,王大东,李基业,姚咏明.低分子肝素对急性胰腺炎患者预后的改善作用[J].中国危重病急救医学,2004,16(12):712-714. 被引量:17
  • 2Angus D C,Bimingham M C,Balk R A,et al. E5 murine monoclonal antiendotoxin antibody in gram- negative sepsis: a randomized controlled trial [J]. JAMA, 2000,283 : 1723 - 1730.
  • 3Annane D, Sebillev V, Froche G,et al. A 3 -lever prognostive classification in sepsis shock based on cortisal levers and cortisol response to corticotropen [J]. JAMA, 2000,283 : 1038 - 1045.
  • 4Linde -zwirble W T,Angusdc D C,Carcillo J,et al. Age -specific indidence and outcame of sepsis in the US[J]. Cirt Care Med,1999,27 (supple 1) :33A.
  • 5Bone R C,Balk R A,Cerra F B,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative the rapies insepsis [J]. Chest, 1992,102 : 1644 - 1655.
  • 6Bernard G R,Vincent J L,Laterre P F,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis[J].New Engl J Meal,2001,344:699 -709.
  • 7Eisele B,Lamy M,Thijs L G,et al. Antithrombin Ⅲ in patients with severe sepsis : a randomize, placebo - controlled, double -blind trial plus a meta -analysis on all randomized placebocon-trolled, double -blind trial with Antithrombin Ⅲ in severe sepsis [J]. Intensive Care Med, 1998,24 : 663 - 672.
  • 8Warren B L, Eid A, Singer P, et al. Caring for the critically ill patient. High- dose antithrombin Ⅲ in severe sepsis :a randomized controlled trial[J]. JAMA, 2001,286 :1869 - 1878.
  • 9Abraham E, Reinbart K, Opal S, et al. Efficacy and safety of recombinant tifacogin(tissue factor pathway inhibitor) in severe sepsis [J]. JAMA, 2003,290 : 238 - 247.
  • 10Patel R T,Deen K I,Youngs D,et al. Interleukin 6 is a prognostic indicator of outcome in severe intre - abdominal sepsis [J].Br J Surg,1994,81:1036- 1038.

共引文献42

同被引文献29

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部